Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

Impact · against what's priced in

Acurx Pharmaceuticals' announcement of a business update and confirmation of regulatory alignment for ibezapolstat Phase 3 trials provides a clear path to registration. While the regulatory guidance reduces execution risk, the upcoming earnings call is the primary near-term catalyst for financial health assessment.

ACXP+0.10

No priced-in read yet